J Cosmet Dermatol:激光和类固醇联合治疗可有效改善甲状腺癌术后瘢痕

2022-07-27 MedSci原创 MedSci原创

甲状腺癌的发生率急剧上升,术后疤痕暴露在容易看到的地方。许多患者对预防术后疤痕表现出更强烈的意愿。到目前为止,已经讨论了许多治疗疤痕的方法。

甲状腺癌的发生率急剧上升,术后疤痕暴露在容易看到的地方。许多患者对预防术后疤痕表现出更强烈的意愿。到目前为止,已经讨论了许多治疗疤痕的方法。近日,发表于J Cosmet Dermatol的一项研究旨在验证早期应用联合治疗是否有助于减少疤痕的形成。

在2019年3月至2019年12月期间,共有64名位于前颈部的甲状腺切除术疤痕大小超过4.5厘米的患者被纳入这项前瞻性试验研究。在术后1个月、2个月和6个月,使用患者和观察者疤痕评估量表(POSAS)进行主观和客观评估。对治疗组和非治疗组的结果进行了比较。

 

结果显示,在PSAS评分中,激光和类固醇治疗组的疼痛、瘙痒感、柔韧度、厚度和缓解度的平均值明显更高(P = 0.009,P = 0.000,P = 0.013,P = 0.002和P = 0.007)。疤痕的颜色值没有显示出明显的差异(P = 0.504)。在OSAS评分中,联合治疗组的瘢痕厚度、舒缓度和表面积评分参数明显较高(p = 0.029、0.035和0.020),而血管、色素和柔韧度在两组之间无明显差异(p = 0.548、p = 0.983和p = 0.128)。

综上所述,该研究结果表明,根据POSAS,早期联合治疗有助于疤痕的改善,达到有意义的程度。研究人员认为,联合疗法在治疗甲状腺疤痕方面显示出了很好的效果。对甲状腺切除术疤痕的长期随访显示,在伤口愈合过程的增殖期和重塑期应用联合治疗,与不治疗相比,对疤痕的预防效果更好。

 

原始出处:

 

Jeong Hyun Cheon, et al.,  Effectiveness of a combination therapy using non-ablative fractional laser and intralesional triamcinolone injection for thyroidectomy scar treatment: a prospective, randomized, blinded pilot study. J Cosmet Dermatol. 2022 Jul;21(7):2793-2800. doi: 10.1111/jocd.14485.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783641, encodeId=48e71e83641d9, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Oct 09 23:53:36 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897042, encodeId=b7be189e042b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 09 03:53:36 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279823, encodeId=d00112e982321, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313505, encodeId=01db1313505b6, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313871, encodeId=b48b13138e1e9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337011, encodeId=7b83133e011b0, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=)]
    2022-10-09 tcm99hq
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783641, encodeId=48e71e83641d9, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Oct 09 23:53:36 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897042, encodeId=b7be189e042b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 09 03:53:36 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279823, encodeId=d00112e982321, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313505, encodeId=01db1313505b6, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313871, encodeId=b48b13138e1e9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337011, encodeId=7b83133e011b0, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=)]
    2023-02-09 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783641, encodeId=48e71e83641d9, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Oct 09 23:53:36 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897042, encodeId=b7be189e042b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 09 03:53:36 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279823, encodeId=d00112e982321, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313505, encodeId=01db1313505b6, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313871, encodeId=b48b13138e1e9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337011, encodeId=7b83133e011b0, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=)]
    2022-07-25 oliver169
  4. [GetPortalCommentsPageByObjectIdResponse(id=1783641, encodeId=48e71e83641d9, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Oct 09 23:53:36 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897042, encodeId=b7be189e042b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 09 03:53:36 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279823, encodeId=d00112e982321, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313505, encodeId=01db1313505b6, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313871, encodeId=b48b13138e1e9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337011, encodeId=7b83133e011b0, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1783641, encodeId=48e71e83641d9, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Oct 09 23:53:36 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897042, encodeId=b7be189e042b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 09 03:53:36 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279823, encodeId=d00112e982321, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313505, encodeId=01db1313505b6, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313871, encodeId=b48b13138e1e9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337011, encodeId=7b83133e011b0, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1783641, encodeId=48e71e83641d9, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Oct 09 23:53:36 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897042, encodeId=b7be189e042b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 09 03:53:36 CST 2023, time=2023-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279823, encodeId=d00112e982321, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313505, encodeId=01db1313505b6, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313871, encodeId=b48b13138e1e9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337011, encodeId=7b83133e011b0, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Jul 25 13:53:36 CST 2022, time=2022-07-25, status=1, ipAttribution=)]

相关资讯

控制血压再添新证!超百万人数据:收缩压每升高1SD,5种常见癌症风险分别增加9%、15%、4%、11%、22%!

Am J Hypertens:未经药物治疗的高血压和癌症事件:两个基于全国人口的数据库分析。

Clinical Endocrinology:10年研究告诉你,甲状腺结节多久复查超声?癌变风险多大?

建议在细胞学评估后,隔2年和5年进行超声检查,此后每4-5年进行一次。

JCEM:甲状腺结节形状可预测甲状腺癌的风险

甲状腺结节越呈球形(长短比值接近1.0),其恶性风险越大。这与年龄、性别和结节大小无关。将结节的球形纳入风险分层系统可以改善个体化临床决策。

甲状腺结节:良性 or 恶性?该如何判读?

分清甲状腺良恶性,这几点要注意!

European Radiology:对于甲状腺癌患者来说,究竟哪些淋巴结有转移的风险呢?

超声(US)是甲状腺癌(DTC)患者术前评估颈部淋巴结(LN)转移的主要影像学手段。

European Radiology:当前基于超声的甲状腺恶性结节风险分层系统在滤泡性肿瘤中的表现

超声是评估恶性肿瘤风险和制定最佳管理策略的一线影像工具,并为治疗决策(手术切除、监测或不随访)提供依据。